In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Eli Lilly EL-468, a phenylenediamine, possesses the delayed-toxicity necessary for a bait toxicant to control colonies of the red imported fire ant, Solenopsis invicta Buren. In laboratory tests it ...

Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.

Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug addiction, making it the first major ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound. Ro is joining other telehealth platforms and Amazon Pharmacy ...

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...

Eli Lilly shares were up more than 4% at last check. Get Monthly Picks of Market's Fastest Movers Eli Lilly And Co LLY shares are trading higher Tuesday after the Biden-Harris Administration ...